Our History
Founded in 2012 as a spin-off from Dalhousie University in Halifax, Nova Scotia, we are now preparing to study our lead products in humans for the first time
ABK Over the Years
2012
ABK Biomedical Founded
Founded at Dalhousie University in 2012, The Three Founders; Interventional Radiologist Robert Abraham, MD, and Material Scientists, Dr’s Daniel Boyd, and Sharon Kehoe, engineered and patented a new platform technology based on “x-ray visible” glass microspheres.
2015
Manufacturing
Production of proprietary glass microspheres began in Halifax, Nova Scotia.
Delivery System
1st Generation delivery system was developed for bland microspheres.
2018
Focus on Yttrium90 (Y90)
ABK’s proprietary glass microspheres were redesigned with a focus on Y90 radioembolization.
New Management Team
An experienced management team was hired under new CEO and President Mike Mangano.
2019
Raised $30M USD in Series B Funding
The largest medical device venture capital raise in Atlantic Canada is used to further develop Eye90 microspheres®, and Easi-Vue™ embolic microspheres.
Multi-year Strategic Partnership with MURR®
The Missouri University Research Reactor Center is the primary irradiation partner for ABK’s radioembolization products.
2020
Eye90 microspheres®
Finalized design and completed pre-clinical testing for Eye90 microspheres® technology.
Accelerated Manufacturing
Commissioned two new manufacturing and cleanroom facilities to accelerate device operations.
2021
Clinical Transition
ABK Biomedical transitioned from a pre-clinical to a clinical-stage company with the initiation of the First-in-Human clinical study with Eye90 microspheres® in November 2021.
2022
Regulatory Execution
ABK Biomedical announced the first patient treated with Eye90 microspheres® in early 2022 and achieved 510(k) clearance from the FDA for Easi-Vue™ embolic microspheres in September 2022.
The ABK Biomedical Team
We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.
ABK Biomedical is an equal opportunity employer offering competitive compensation packages.
ABK's Business Partners
ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.
Research Partners
Development Partners
Corporate Offices
Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada
T. 902.442.4009
Orange County Office
555 Corporate Drive
Suite 105
Ladera Ranch, CA, 92694
USA
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.
Copyright 2022 - All International Rights Reserved